Tekrardan Hoşgeldiniz
Cointime'ın Hizmet Şartları'ini kabul etmek ve Cointime'ın Gizlilik Politikası'inin sizin için geçerli olduğunu onaylamak için "Giriş "a tıklayın.
Cointime’a Katıl
Çoktan Hesabın Var mı?
Cointime'ın <a class="underline" href="#term-of-service">Hizmet Şartları</a>'ini kabul etmek ve Cointime'ın a class="underline" href="#privacy-policy">Gizlilik Politikası</a>'inin sizin için geçerli olduğunu onaylamak için "page.Sign up "a tıklayın.
Giriş Yap
Kayıt Ol
Posta kutunuz
Gelen kutunuzu kontrol edin
Giriş yapmak için emaildeki bağlantıya tıklayın.
Kayıt olmak için emaildeki bağlantıya tıklayın.
Abogen Biosciences
company
About
Abogen Biosciences is a discovery stage biotechnology company focuses on developing nucleic acid-based RNA and DNA therapeutics.
- 1 - 10
Details
- Last Funding Type
- Series C
- Last Funding Money Raised
- $300M
- Industries
- Biotechnology,Genetics,Life Science
- Founded date
- Jan 1, 2019
- Number Of Employee
- 1 - 10
- Operating Status
- Active
Abogen Biosciences is a discovery stage biotechnology company focuses on developing nucleic acid-based (RNA and DNA) therapeutics for treatment of cancer and infectious diseases.
Funding Rounds
Number of Funding Rounds
Total Funding Amount
2
$1.30B
Abogen Biosciences has raised a total of
$1.30B
in funding over 2 rounds. Their latest funding was raised on
Nov 29, 2021 from a Series C round.
| Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
|---|---|---|---|---|---|---|
| Nov 29, 2021 | Series C | $300M | 3 | — | — | Detail |
| Aug 19, 2021 | Series C | $1B | 3 |
Lilly Asia Ventures
|
— | Detail |
Investors
Number of Lead Investors
Number of Investors
1
6
Abogen Biosciences is funded by 6 investors.
Lilly Asia Ventures
and MiraeAsset Financial Group
are the most recent investors.
| Investor Name | Lead Investor | Funding Round |
|---|---|---|
|
Lilly Asia Ventures
|
Yes | Series C |
|
|
— | Series C |
|
|
— | Series C |
|
|
— | Series C |
Abu Dhabi Investment Authority
|
— | Series C |
Gaorong Capital
|
— | Series C |
Share
Twitter
LinkedIn
Line
Facebook
Telegram
Email
Page Link
